Wikidata

(Q61862227)

English

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

clinical trial

In more languages

Statements

title
A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM) (English)
0 references
sponsor
Celgene
0 references
country
Canada
0 references
France
0 references
Germany
0 references
Italy
0 references
Netherlands
0 references
Spain
0 references
start time
11 January 2016
0 references
end time
10 January 2017
0 references
number of participants
114
0 references
research intervention
dexamethasone acetate
0 references
(RS)-cyclophosphamide
0 references
pomalidomide
0 references
thalidomide
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61862227&oldid=2110015179"